



**Preferred  
Research  
Partners**

Curriculum Vitae

**Kelly Knight, CCRP**

Research Affiliation

Preferred Research Partners, Inc.

11219 Financial Center Parkway,

Suite 320

Little Rock, AR 72211

(501) 553-9987 Phone

(501) 553-9986 Fax

K Knight, CCRP

Signature

08 Feb 2017

Date

**Kelly Diane Knight, CCRP**  
[kknight@preferredresearchpartners.com](mailto:kknight@preferredresearchpartners.com)  
501-553-9987 x.108

### **Office**

Paul E. Wylie, M.D., P.A. (Clinic Office)  
11219 Financial Center Parkway, Suite 315  
Little Rock, AR 72211  
Phone: 501-661-9191 x.108 Fax: 501-661-1991

Arkansas Center for Sleep Medicine, PLLC (Polysomnography Lab)  
11219 Financial Center Parkway, Suite 101  
Little Rock, AR 72211  
Phone: 501-661-9191 x.108 Fax: 501-661-1991

Preferred Research Partners, Inc.  
11219 Financial Centre Parkway, Suite 320  
Little Rock, AR 72211  
Phone: 501-553-9987 x.108 fax: 501-553-9986

### **Education**

2001-2003: Pulaski Technical College  
Core Education Courses

January 2000 – May 2000 Louisiana Technical College  
Certificate for Nursing Assistant

### **Certifications/Licensures**

SOCRA CCRP certification number: 36869

### **Work Experience**

January 2009-present:

Study Coordinator, Preferred Research Partners, Inc.- Little Rock, AR  
IRB submissions, marketing, recruiting patients, ensuring all equipment functional & calibrated, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, creation of source documents, regulatory, filing, scheduling, AE/SAE reporting, laboratory collection and processing.

July 2007-present:

Study Coordinator, Arkansas Center for Sleep Medicine- Little Rock, AR  
Duties include IRB submissions, marketing, recruiting patients, ensuring all equipment functional & calibrated, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, creation of source documents, regulatory, filing, scheduling, AE/SAE reporting, laboratory collection and processing.

July 2005-July 2006:

Study Coordinator, Gulf Coast Research Associates, LLC-Baton Rouge, La.

Recruiting patients, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, filing, scheduling, AE/SAE reporting, laboratory processing.

2003-2006: Caring Hands Home Health Services Baton Rouge, LA

Patient Care Attendant/Caregiver

Responsible for assisting an autistic child with activities of daily living, completing daily progress notes, following specific curriculums and behavior protocols, creation of compliance gaining and maintaining techniques and following through with them and keeping up with detailed daily records of progression/digression.

2000-2002: Life Skills Technician, Arkansas Pediatric Facility North Little Rock, AR

Duties providing complete care for physically and /or mentally disabled pediatrics in a long term care facility. Completing detailed charting and record keeping of food/liquid intake, voids/bms, positioning, behavior and overall well-being.

### **Presentations & Academic Research**

2/2010: "Effective Subject Recruitment & Retention Strategies" presentation to all RLS sites on A0081185 for United Biosource Corporation

### **Research Experience**

#### **Pharmaceutical:**

- 2005: Boehringer Ingleheim ProFess – Second Stroke Prevention Study
- 2005: GSK, Restless Legs Syndrome
- 2006: Xenoport, Restless Legs Syndrome
- 2007: Xenoport, Restless Legs Syndrome (PK)– XP081
- 2007: Xenoport, Restless Legs Syndrome – XP053
- 2007: Takeda, Delayed Sleep Phase Syndrome (polysomnography)– 01-04-TL-375-044
- 2007: Sanofi-Aventis, Sleep Maintenance Insomnia – LTE6673 (SAMS)
- 2007: Xenoport, Restless Legs Syndrome – XP055
- 2007: Organon, Chronic Primary Insomnia (polysomnography) – 176002
- 2007: Organon, Chronic Primary Insomnia – 176004
- 2007: Pfizer, Primary Insomnia – A4251037
- 2008: Pfizer, Non-Restorative Sleep (polysomnography) – A4251033
- 2008: Lilly, Primary & Secondary Insomnia – 12K-MC-ZZAD
- 2009: Pfizer, Restless Legs Syndrome – A0081186
- 2009: Pfizer, RLS Patient Reported Outcomes – PI6034A
- 2009: Pfizer, Fibromyalgia & Sleep Maintenance Insomnia – A0081165
- 2009: Pfizer, Restless Legs Syndrome (polysomnography) – A0081185
- 2010: Pfizer, Restless Legs Syndrome – A0081184
- 2010: Sepracor, Attention Deficit Disorder & Insomnia in Children (polysomnography) – 190-246
- 2010: Sepracor, Attention Deficit Disorder & Insomnia in Children (rollover & treatment naïve) – 190-247
- 2010: Romark Laboratories/SGS, Acute Uncomplicated Influenza – RM08-3001
- 2010: Eli Lilly & Company, Sickle Cell Anemia – H7T-MC-TAEK(a)
- 2010: AstraZeneca, Major Depressive Disorder – D413C00004

- 2010: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS2001
- 2011: AstraZeneca, Opioid Induced Constipation – D3820C00005 (KODIAC 5)
- 2011: AstraZeneca, Opioid Induced Constipation – D3820C00008 (KODIAC 8)
- 2011: Anchen Pharmaceuticals, Chronic Idiopathic Constipation – 71060001
- 2011: Impax Pharmaceuticals, Restless Legs Syndrome – IPX159-B11-02
- 2011: UCB, Restless Legs Syndrome in Adolescents – SP1004
- 2011: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102073
- 2012: Synergy Pharmaceuticals, Chronic Idiopathic Constipation – SP304-20210
- 2012: UCB, Restless Legs Syndrome in Adolescents – SP1005
- 2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102077
- 2012: Forest Research Institute, Hypertension – NAC-MD-01
- 2012: Ardea BioSciences, Gout – RDEA594-301
- 2012: Orexigen, Obesity & Cardiovascular Outcomes – NB-CVOT
- 2012: Novartis, High Triglycerides – CLCQ908C2201
- 2012: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS3001
- 2012: Lexicon Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – LX1033-1.201
- 2012: Tioga Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – ASMP3001
- 2012: Shionogi, Inc., Opioid Induced Constipation – 1107V9221
- 2012: Tsumura Pharmaceuticals, Crohn's Disease – TU100P2T2
- 2012: Coronado Biosciences, Crohn's Disease – CNDO-201-003
- 2012: Shire, GERD – SPD557-206
- 2012: UCB, Healthy Adult, Phase I – SP1031
- 2012: UCB, Restless Legs Syndrome – RL0003
- 2012: GSK, Restless Legs Syndrome – RXP114025
- 2013: Ardea BioSciences, Gout – RDEA594-306
- 2013: Dr. Reddy's Laboratories, Chronic Idiopathic Constipation – DRL-USG01-L/2012
- 2013: Purdue Pharma L.P., Chronic Low Back Pain & Opioid-Induced Constipation – ONU3705
- 2013: Cubist Pharmaceuticals, Inc., Opioid-induced Constipation – 5945-SOIC-12-05
- 2013: Cubist Pharmaceuticals, Inc., Opioid-induced Constipation – 5945-OIC-12-04
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000080
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000081
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (OLE CIC) – SP304203-01
- 2013: Shionogi, Inc., Opioid Induced Constipation – 1315V9232
- 2013: Menarini, Diarrhea-Predominant Irritable Bowel Syndrome – NAK-07 (IRIS-4)
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (CIC3) – SP304203-00
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-003
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-004
- 2014: Eisai, Long-Term incidence of MACE events & conversion to Type II Diabetes Mellitus in Obese & Overweight Subjects with Cardiovascular Disease or Multiple CV Risk Factors – APD356-G000-401
- 2015: Rhythm Pharmaceuticals, Diabetic Gastroparesis -RM-131-009

- 2015: Jazz Pharmaceuticals, Narcolepsy & Excessive Daytime Sleepiness - 14-002
- 2015: Jazz Pharmaceuticals, Obstructive Sleep Apnea & Excessive Daytime Sleepiness - 14-003
- 2015: Jazz Pharmaceuticals, Long-term extension study for Obstructive Sleep Apnea or Narcolepsy with Excessive Daytime Sleepiness - 14-005
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia – NBI-98854-1304 (KINECT3)
- 2015: Theravance, Diabetic or Idiopathic Gastroparesis – 0099
- 2015: Synergy Pharmaceuticals, Inc., Irritable Bowel Syndrome- Constipation - SP304203-04

- 2015: Forest Research Institute, Inc., Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic Constipation -LIN-MD-10
- 2015: Edgemont Pharmaceuticals, Generalized Anxiety Disorder - EDG004-003
- 2015: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3001 (TRANSFORM-I)
- 2015: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3003 (SUSTAIN- I)
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia -NBI-98854-1402 (KINECT4)
- 2015: Naurex Inc., Major Depressive Disorder -NRX1074-C-202
- 2015: Gilead, Ulcerative Colitis -GS-US-326-1100
- 2015: Sunovion Pharmaceuticals, Adult Attention Deficit Hyperactivity Disorder (ADHD) - SEP360-301
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis -000174
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis -000175
- 2016: Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) - IDN-6556-12
- 2016: Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) - 'SP304203-06
- 2016: Janssen Research & Development, Treatment-resistant Depression - ESKETINTRD3008
- 2016: Eisai Pharmaceuticals, Elderly Insomnia -E2006-G000-304
- 2016: Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome - 1VIT14037
- 2016: Braintree Laboratories, Chronic Constipation -BLI400-302
- 2016: Braintree Laboratories, Opioid Induced Constipation -BLI801-203

**Device:**

- 10/2007: Respiroics Inc. – The Impact of BiPAP AutoSVTM on Central Disregulated Breathing & Chronic Pain Patients (MR-0728-ASV3-MS)
- 10/2007: Restore Medical, Inc. – A Randomized, Placebo-Controlled Study of the Pillar Palatal Implant System with CPAP (protocol 845)
- 01/2008: Respiroics Inc. – Stardust Screening Study (MR-0735-SDSS-MS)
- 02/2008: Respiroics Inc. – Evaluation of a Positive Air Pressure Delivery Systems on Adherence & Outcomes (System One versus Better Together MR-0733-SYS1-SS)

- 08/2008: Respiroics Inc. – Evaluation of Software Enhancements to the Respiroics BiPAP AutoSV device (MR-0731-ASV3-MS)
- 04/2009: Respiroics Inc. – User Preference & Validation Evaluation of the New BiPAP autoSV3 device (ST-0906-ASV3VAL-MS)
- 07/2009: Respiroics Inc. – Evaluation of the Q-Series Auto Device for the Treatment of OSA (ST-0925-AQVM-MS-G/W)
- 2/2010: Philips-Respiroics Inc. – Engineering Evaluation of the Next Generation of autoSV Devices (ST-0937-ASV4ENG-MS)
- 6/2010: Philips Respiroics – Evaluation of the Philips Respiroics BiPAP autoSV devices in subjects with Sleep Disorders (ST-1007-ASV4-MS)
- 12/2010: Philips Respiroics – Philips Respiroics BiPAP autoSV4 User Preference Trial (ST-1030-ASV4PREF-SS)
- 8/2011: Philips Respiroics – BiPAP autoSV System One Advanced in Patients with Chronic Pain and Sleep Disordered Breathing (SDBPM-2011-01)
- 9/2011: Philips Respiroics – Automated Graduated CPAP for Improved Adherence in Newly Diagnosed OSA Patients: Multicenter Trial (AR-1112-AGPAP-MS)
- 6/2012: Philips Respiroics – BiPAP autoSV Advanced in Central Apnea Patients (ST-1001-ASVWO-MS)
- 7/2012: Philips Respiroics – User Preference/Validation Evaluation of the New Phillips Respiroics PAP Application (ST1203-APP-MS)
- 6/2013: Philips Respiroics – Evaluation of the OmniLab 2.0 (ST-1311-OmniLab-MS)

### **Training Documentation**

April 2016	IATA Training Transporting Dangerous Goods
April 2015	CITI Program
June 2014	National Institutes of Health Web Base Training: Protecting Human Research Participants
March 2014	IATA training
October 2013	Stericycle Blood Borne Pathogen training
September 2013	SOCRA CCRP re-certification

June 2012	National Institutes of Health Web Base Training: Protecting Human Research Participants
March 2012	IATA training
June 2011	SOCRA CCRP certification
January 2011	IATA training
July 2010	Quintiles ICH/GCP Training for Clinical Sites
June 2010	National Institutes of Health Web Base Training: Protecting Human Research Participants
January 2010	InForm 4.6 Phase Forward training
April 2009	IATA training
December 2008	Pfizer OC-RDC 4.5.3 training
January 2008	Stericycle Blood Borne Pathogen training
December 2007	Pfizer Investigator Site Data Capture course